{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:17:19Z","timestamp":1787505439175,"version":"build-2736575974"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsmedizin Greifswald"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The association between metabolic dysfunction-associated steatotic liver disease (MASLD) and serum lipoprotein(a) (Lp[a]) levels remains controversial, with no sex- or menopausal status-stratified analyses. We aimed to analyse the associations between MASLD, liver fat content (LFC) and transaminases with Lp(a) concentrations stratified by sex and menopausal status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed data from 3825 individuals (1961 females; 51.3%) aged 32 to 70 years from the SHIP-START-0 cohort, and from 28,504 individuals (14,926 females; 52.4%) aged 38 to 72 years from the UK Biobank cohort. MASLD was determined by liver ultrasound examinations in SHIP-STAR-0 and by magnetic resonance imaging in UK Biobank. We examined sex- and menopausal status-specific associations of MASLD, LFC, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase (GGT) with lipoprotein(a) [Lp(a)] concentrations, after adjustment for age, body mass index, haemoglobin A1c, glucose-lowering medication use, hypertension, smoking, and alcohol consumption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In SHIP-START-0, MASLD, higher ALT, AST, and GGT levels were independently associated with lower Lp(a) concentrations only in males but not in females. However, after stratification by menopausal status, higher ALT levels were associated with lower Lp(a) concentrations in postmenopausal females, but not in premenopausal females. In UK Biobank, MASLD severity (moderate and severe), higher LFC, and higher serum transaminase levels were independently associated with lower Lp(a) concentrations in males. Higher LFC was also associated with lower Lp(a) concentrations in females, but serum liver enzymes were not. After stratification by menopausal status, MASLD severity and higher LFC were associated with lower Lp(a) concentrations in postmenopausal females, but not in premenopausal females. Males with MASLD had 24% and 9% lower Lp(a) concentrations than those without MASLD in SHIP-START-0 and UK Biobank.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings from two large community-based studies show that MASLD and higher LFC and ALT values were independently associated with lower Lp(a) concentrations in postmenopausal females and males. Future studies are needed to determine whether the cardiovascular risk in patients with MASLD remains elevated even when Lp(a) concentrations are reduced and whether these patients require more intensive treatment to further reduce Lp(a) concentrations below the currently recommended cut-off values.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-026-03289-8","type":"journal-article","created":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T06:03:01Z","timestamp":1783836181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sex- and menopause-specific inverse associations between metabolic dysfunction\u2013associated steatotic liver disease and serum lipoprotein(a) concentrations: evidence from SHIP and UK Biobank"],"prefix":"10.1186","volume":"25","author":[{"given":"J\u00falia Galbiati","family":"de Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Ittermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Schipf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nele","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Nauck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio Hiroshi","family":"Miname","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1bio","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul Dias","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena-Rima","family":"Ghadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Di Vece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bahls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Steinhagen-Thiessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Templin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00e1gila Raquel Teixeira","family":"Damasceno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello Ricardo Paulista","family":"Markus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,12]]},"reference":[{"key":"3289_CR1","unstructured":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet (London, England). 2020, 396(10258):1204\u20131222."},{"issue":"25","key":"3289_CR2","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, et al. Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982\u20133021.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"3289_CR3","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology (Baltimore MD). 2023;78(6):1966\u201386.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"8s","key":"3289_CR4","first-page":"S4","volume":"40","author":"LR Brunham","year":"2024","unstructured":"Brunham LR, Lonn E, Mehta SR. Dyslipidemia and the current state of cardiovascular disease: epidemiology, risk factors, and effect of lipid lowering. Can J Cardiol. 2024;40(8s):S4\u201312.","journal-title":"Can J Cardiol"},{"issue":"39","key":"3289_CR5","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1093\/eurheartj\/ehaf281","volume":"46","author":"MRP Markus","year":"2025","unstructured":"Markus MRP, Ittermann T, Mari\u00f1o Coronado J, Schipf S, Bahls M, K\u00f6nemann S, Chamling B, V\u00f6lzke H, Damasceno NRT, Santos RD, et al. Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events. Eur Heart J. 2025;46(39):3863\u201374.","journal-title":"Eur Heart J"},{"issue":"4","key":"3289_CR6","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1210\/endrev\/bnab037","volume":"43","author":"AJ Berberich","year":"2022","unstructured":"Berberich AJ, Hegele RA. A modern approach to dyslipidemia. Endocr Rev. 2022;43(4):611\u201353.","journal-title":"Endocr Rev"},{"key":"3289_CR7","doi-asserted-by":"crossref","unstructured":"Lampsas S, Xenou M, Oikonomou E, Pantelidis P, Lysandrou A, Sarantos S, Goliopoulou A, Kalogeras K, Tsigkou V, Kalpis A et al. Lipoprotein(a) in atherosclerotic diseases: from pathophysiology to diagnosis and treatment. Molecules 2023, 28(3).","DOI":"10.3390\/molecules28030969"},{"issue":"12","key":"3289_CR8","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1111\/jgh.16768","volume":"39","author":"A Nikoli","year":"2024","unstructured":"Nikoli A, Orfanidou M, Goulas A, Goulis DG, Polyzos SA. Circulating lipoprotein(a) in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2024;39(12):2572\u201381.","journal-title":"J Gastroenterol Hepatol"},{"key":"3289_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1146\/annurev-pharmtox-031023-100609","volume":"64","author":"E Tasdighi","year":"2024","unstructured":"Tasdighi E, Adhikari R, Almaadawy O, Leucker TM, Blaha MJ. LP(a): structure, genetics, associated cardiovascular risk, and emerging therapeutics. Annu Rev Pharmacol Toxicol. 2024;64:135\u201357.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"9","key":"3289_CR10","doi-asserted-by":"publisher","first-page":"e035353","DOI":"10.1161\/JAHA.124.035353","volume":"14","author":"G Kaur","year":"2025","unstructured":"Kaur G, Berman AN, Biery DW, Besser SA, Wu WY, Weber B, Honigberg MC, Nasir K, Gulati M, Di Carli MF, et al. Sex differences in the association between lipoprotein(a) and cardiovascular outcomes: the MGB Lp(a) registry. J Am Heart Association. 2025;14(9):e035353.","journal-title":"J Am Heart Association"},{"key":"3289_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.atherosclerosis.2022.11.016","volume":"363","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F. Lipoprotein(a) and cardiovascular disease: make use of the knowledge we have. Atherosclerosis. 2022;363:75\u20137.","journal-title":"Atherosclerosis"},{"key":"3289_CR12","doi-asserted-by":"crossref","unstructured":"Fogacci F, Yerlita\u015f S, Giovannini M, Zarars\u0131z G, Lido P, Borghi C, Cicero AFG. Sex X time interactions in Lp(a) and LDL-C response to evolocumab. Biomedicines 2023, 11(12).","DOI":"10.3390\/biomedicines11123271"},{"key":"3289_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2022.06.1023","volume":"355","author":"SB Simony","year":"2022","unstructured":"Simony SB, Mortensen MB, Langsted A, Afzal S, Kamstrup PR, Nordestgaard BG. Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: The Copenhagen General Population Study. Atherosclerosis. 2022;355:76\u201382.","journal-title":"Atherosclerosis"},{"issue":"1","key":"3289_CR14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12933-021-01363-x","volume":"20","author":"MRP Markus","year":"2021","unstructured":"Markus MRP, Ittermann T, Schipf S, Bahls M, Nauck M, V\u00f6lzke H, Santos RD, Peters A, Zeller T, Felix SB, et al. Association of sex-specific differences in lipoprotein(a) concentrations with cardiovascular mortality in individuals with type 2 diabetes mellitus. Cardiovasc Diabetol. 2021;20(1):168.","journal-title":"Cardiovasc Diabetol"},{"issue":"15","key":"3289_CR15","first-page":"270","volume":"119","author":"N Buchmann","year":"2022","unstructured":"Buchmann N, Ittermann T, Demuth I, Markus MRP, V\u00f6lzke H, D\u00f6rr M, Friedrich N, Lerch MM, Santos RD, Schipf S, et al. Lipoprotein(a) and metabolic syndrome. Deutsches Arzteblatt Int. 2022;119(15):270\u20136.","journal-title":"Deutsches Arzteblatt Int"},{"issue":"2","key":"3289_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jama.2025.19615","volume":"335","author":"H Tilg","year":"2026","unstructured":"Tilg H, Petta S, Stefan N, Targher G. Metabolic dysfunction\u2013associated steatotic liver disease in adults: a review. JAMA. 2026;335(2):163\u201374.","journal-title":"JAMA"},{"issue":"1","key":"3289_CR17","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12933-024-02434-5","volume":"23","author":"H Zheng","year":"2024","unstructured":"Zheng H, Sechi LA, Navarese EP, Casu G, Vidili G. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Cardiovasc Diabetol. 2024;23(1):346.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3289_CR18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s12933-025-02941-z","volume":"24","author":"M Gan","year":"2025","unstructured":"Gan M, Chen B, Qin M, Zhang L, Wang X. Association between atherogenic index of plasma (AIP) and all-cause and cardiovascular mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a cohort study based on NHANES 1999\u20132018. Cardiovasc Diabetol. 2025;24(1):391.","journal-title":"Cardiovasc Diabetol"},{"key":"3289_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2020.02.026","volume":"299","author":"K Konishi","year":"2020","unstructured":"Konishi K, Miyake T, Furukawa S, Senba H, Kanzaki S, Nakaguchi H, Yukimoto A, Nakamura Y, Watanabe T, Koizumi Y, et al. Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor. Atherosclerosis. 2020;299:32\u20137.","journal-title":"Atherosclerosis"},{"issue":"6","key":"3289_CR20","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jacl.2023.09.003","volume":"17","author":"A Mehta","year":"2023","unstructured":"Mehta A, Lee TB, Alebna P, Grandhi GR, Dixon DL, Salloum FN, Sanyal AJ, Siddiqui MS. Discordant association of nonalcoholic fatty liver disease with lipoprotein(a) and markers of atherogenic dyslipidemia. J Clin Lipidol. 2023;17(6):828\u201333.","journal-title":"J Clin Lipidol"},{"issue":"3","key":"3289_CR21","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/BF01324255","volume":"46","author":"U John","year":"2001","unstructured":"John U, Greiner B, Hensel E, L\u00fcdemann J, Piek M, Sauer S, Adam C, Born G, Alte D, Greiser E, et al. Pomerania (SHIP): a health examination survey in an east German region: objectives and design. Soz Praventivmed. 2001;46(3):186\u201394. Study of Health In.","journal-title":"Soz Praventivmed"},{"issue":"2","key":"3289_CR22","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/ije\/dyp394","volume":"40","author":"H V\u00f6lzke","year":"2011","unstructured":"V\u00f6lzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N, Aumann N, Lau K, Piontek M, Born G, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294\u2013307.","journal-title":"Int J Epidemiol"},{"issue":"6","key":"3289_CR23","doi-asserted-by":"publisher","first-page":"e372","DOI":"10.1093\/ije\/dyac034","volume":"51","author":"H V\u00f6lzke","year":"2022","unstructured":"V\u00f6lzke H, Sch\u00f6ssow J, Schmidt CO, J\u00fcrgens C, Richter A, Werner A, Werner N, Radke D, Teumer A, Ittermann T, et al. Cohort profile update: the study of health in pomerania (SHIP). Int J Epidemiol. 2022;51(6):e372\u201383.","journal-title":"Int J Epidemiol"},{"issue":"3","key":"3289_CR24","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779.","journal-title":"PLoS Med"},{"issue":"7726","key":"3289_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","volume":"562","author":"C Bycroft","year":"2018","unstructured":"Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Delaneau O, O\u2019Connell J, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203\u20139.","journal-title":"Nature"},{"issue":"1","key":"3289_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jacc.2021.03.342","volume":"78","author":"R Caleyachetty","year":"2021","unstructured":"Caleyachetty R, Littlejohns T, Lacey B, Be\u0161evi\u0107 J, Conroy M, Collins R, Allen N. United Kingdom Biobank (UK Biobank): JACC Focus Seminar 6\/8. J Am Coll Cardiol. 2021;78(1):56\u201365.","journal-title":"J Am Coll Cardiol"},{"key":"3289_CR27","doi-asserted-by":"publisher","first-page":"100693","DOI":"10.1016\/j.lanepe.2023.100693","volume":"32","author":"CT Rentsch","year":"2023","unstructured":"Rentsch CT, Garfield V, Mathur R, Eastwood SV, Smeeth L, Chaturvedi N, Bhaskaran K. Sex-specific risks for cardiovascular disease across the glycaemic spectrum: a population-based cohort study using the UK Biobank. Lancet Reg health Europe. 2023;32:100693.","journal-title":"Lancet Reg health Europe"},{"issue":"12","key":"3289_CR28","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.3748\/wjg.v11.i12.1848","volume":"11","author":"H Volzke","year":"2005","unstructured":"Volzke H, Robinson DM, Kleine V, Deutscher R, Hoffmann W, Ludemann J, Schminke U, Kessler C, John U. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol. 2005;11(12):1848\u201353.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"3289_CR29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.7326\/0003-4819-132-2-200001180-00004","volume":"132","author":"S Bellentani","year":"2000","unstructured":"Bellentani S, Saccoccio G, Masutti F, Croc\u00e8 LS, Brandi G, Sasso F, Cristanini G, Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132(2):112\u20137.","journal-title":"Ann Intern Med"},{"issue":"2","key":"3289_CR30","doi-asserted-by":"publisher","first-page":"e0172921","DOI":"10.1371\/journal.pone.0172921","volume":"12","author":"HR Wilman","year":"2017","unstructured":"Wilman HR, Kelly M, Garratt S, Matthews PM, Milanesi M, Herlihy A, Gyngell M, Neubauer S, Bell JD, Banerjee R, et al. Characterisation of liver fat in the UK Biobank cohort. PLoS ONE. 2017;12(2):e0172921.","journal-title":"PLoS ONE"},{"issue":"1","key":"3289_CR31","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s00261-018-1701-2","volume":"44","author":"A Mojtahed","year":"2019","unstructured":"Mojtahed A, Kelly CJ, Herlihy AH, Kin S, Wilman HR, McKay A, Kelly M, Milanesi M, Neubauer S, Thomas EL, et al. Reference range of liver corrected T1 values in a population at low risk for fatty liver disease-a UK Biobank sub-study, with an appendix of interesting cases. Abdom Radiol (New York). 2019;44(1):72\u201384.","journal-title":"Abdom Radiol (New York)"},{"issue":"2","key":"3289_CR32","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jhep.2020.03.032","volume":"73","author":"CA Parisinos","year":"2020","unstructured":"Parisinos CA, Wilman HR, Thomas EL, Kelly M, Nicholls RC, McGonigle J, Neubauer S, Hingorani AD, Patel RS, Hemingway H, et al. Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis. J Hepatol. 2020;73(2):241\u201351.","journal-title":"J Hepatol"},{"issue":"7","key":"3289_CR33","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/j.1478-3231.2010.02371.x","volume":"31","author":"H V\u00f6lzke","year":"2011","unstructured":"V\u00f6lzke H, Alte D, Ittermann T, Schmidt CO, Rettig R, Mayerle J, Lowenfels AB, Lerch MM, Nauck M. Subjects with sonographical hepatic steatosis should be excluded from studies to establish upper reference levels of serum transaminases. Liver Int. 2011;31(7):985\u201393.","journal-title":"Liver international: official J Int Association Study Liver"},{"key":"3289_CR34","doi-asserted-by":"crossref","unstructured":"Ke\u00dfler A, Schumacher M, Wood WG. Immunoluminometric assays for the quantification of apolipoproteins A-I, B, C-II, Apolipoprotein(a) and Lipoprotein(a). In.: Kooperation de Gruyter; 1994.","DOI":"10.1515\/cclm.1994.32.3.127"},{"key":"3289_CR35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1471-2288-11-103","volume":"11","author":"R Haring","year":"2011","unstructured":"Haring R, Feng YS, Moock J, V\u00f6lzke H, D\u00f6rr M, Nauck M, Wallaschofski H, Kohlmann T. Self-perceived quality of life predicts mortality risk better than a multi-biomarker panel, but the combination of both does best. BMC Med Res Methodol. 2011;11:103.","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"3289_CR36","doi-asserted-by":"publisher","first-page":"e33084","DOI":"10.1371\/journal.pone.0033084","volume":"7","author":"HJ Schneider","year":"2012","unstructured":"Schneider HJ, Wallaschofski H, V\u00f6lzke H, Markus MR, Doerr M, Felix SB, Nauck M, Friedrich N. Incremental effects of endocrine and metabolic biomarkers and abdominal obesity on cardiovascular mortality prediction. PLoS ONE. 2012;7(3):e33084.","journal-title":"PLoS ONE"},{"issue":"1","key":"3289_CR37","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12933-024-02263-6","volume":"23","author":"A Colantoni","year":"2024","unstructured":"Colantoni A, Bucci T, Cocomello N, Angelico F, Ettorre E, Pastori D, Lip GYH, Del Ben M, Baratta F. Lipid-based insulin-resistance markers predict cardiovascular events in metabolic dysfunction associated steatotic liver disease. Cardiovasc Diabetol. 2024;23(1):175.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3289_CR38","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1186\/s12933-025-02928-w","volume":"24","author":"L Liu","year":"2025","unstructured":"Liu L, Yu G, Ji X, Wang Y, He H. Associations of six insulin resistance-related indices with the risk and progression of cardio-renal-metabolic multimorbidity: evidence from the UK biobank. Cardiovasc Diabetol. 2025;24(1):377.","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"3289_CR39","doi-asserted-by":"publisher","first-page":"e70042","DOI":"10.1111\/crj.70042","volume":"18","author":"X Sun","year":"2024","unstructured":"Sun X, Guo Z, Zhang Y, Liu Z, Xiong J, Cai M, Tan J, Lin Y, Yu Z, Du K, et al. Liver function biomarkers and lung cancer risk: a prospective cohort study in the UK Biobank. Clin Respir J. 2024;18(12):e70042.","journal-title":"Clin Respir J"},{"issue":"10459","key":"3289_CR40","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","volume":"404","author":"BG Nordestgaard","year":"2024","unstructured":"Nordestgaard BG, Langsted A. Lipoprotein(a) and cardiovascular disease. Lancet (London England). 2024;404(10459):1255\u201364.","journal-title":"Lancet (London England)"},{"issue":"1","key":"3289_CR41","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/s12933-025-03004-z","volume":"24","author":"S Pelusi","year":"2025","unstructured":"Pelusi S, Macchi C, Malvestiti F, Margarita S, De Matteis I, Periti G, Rondena J, Mira S, Iemma F, Tranchina M, et al. Interplay among lipoprotein(a), hepatic and vascular damage in individuals with metabolic dysfunction. Cardiovasc Diabetol. 2025;24(1):447.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"3289_CR42","doi-asserted-by":"publisher","first-page":"e70208","DOI":"10.1111\/liv.70208","volume":"45","author":"T Xiao","year":"2025","unstructured":"Xiao T, Liu HH, Tian N, Lian LY, Miao KW, Li YT, Chen LL, Yuan HY, Du M, Wu S, et al. Association of plasma lipoprotein(a) with major adverse cardiovascular events in MASLD with or without advanced liver fibrosis. Liver Int 2025;45(8):e70208.","journal-title":"Liver international: official J Int Association Study Liver"},{"issue":"8","key":"3289_CR43","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.cgh.2024.10.018","volume":"23","author":"H Fan","year":"2025","unstructured":"Fan H, Kouvari M, Mingrone G, George J, Papatheodoridis G, Valenzuela-Vallejo L, Liu Z, Chen X, Zhang T, Mantzoros CS. Lipoprotein (a) in the full spectrum of metabolic dysfunction-associated steatotic liver disease: evidence from histologically and genetically characterized cohorts. Clin Gastroenterol Hepatol 2025;23(8):1356\u2013e13651355.","journal-title":"Clin Gastroenterol hepatology: official Clin Pract J Am Gastroenterological Association"},{"issue":"10470","key":"3289_CR44","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/S0140-6736(24)02089-0","volume":"404","author":"TE Strandberg","year":"2024","unstructured":"Strandberg TE, Kovanen PT, Lloyd-Jones DM, Raal FJ, Santos RD, Watts GF. Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S). Lancet (London England). 2024;404(10470):2462\u201375.","journal-title":"Lancet (London England)"},{"issue":"1","key":"3289_CR45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s001250051110","volume":"42","author":"DM Neele","year":"1999","unstructured":"Neele DM, de Wit EC, Princen HM. Insulin suppresses apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes. Diabetologia. 1999;42(1):41\u20134.","journal-title":"Diabetologia"},{"issue":"9093","key":"3289_CR46","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/S0140-6736(05)63572-6","volume":"350","author":"K Matsumoto","year":"1997","unstructured":"Matsumoto K, Miyake S, Yano M, Ueki Y, Tominaga Y. Increase of lipoprotein (a) with troglitazone. Lancet (London England). 1997;350(9093):1748\u20139.","journal-title":"Lancet (London England)"},{"issue":"4","key":"3289_CR47","doi-asserted-by":"publisher","first-page":"302","DOI":"10.2337\/diacare.14.4.302","volume":"14","author":"SM Haffner","year":"1991","unstructured":"Haffner SM, Tuttle KR, Rainwater DL. Decrease of lipoprotein(a) with improved glycemic control in IDDM subjects. Diabetes Care. 1991;14(4):302\u20137.","journal-title":"Diabetes Care"},{"issue":"3","key":"3289_CR48","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/hep4.1830","volume":"6","author":"M Meroni","year":"2022","unstructured":"Meroni M, Longo M, Lombardi R, Paolini E, Macchi C, Corsini A, Sirtori CR, Fracanzani AL, Ruscica M, Dongiovanni P. Low lipoprotein(a) levels predict hepatic fibrosis in patients with nonalcoholic fatty liver disease. Hepatol Commun. 2022;6(3):535\u201349.","journal-title":"Hepatol Commun"},{"issue":"6","key":"3289_CR49","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1161\/01.ATV.18.6.984","volume":"18","author":"R Ramharack","year":"1998","unstructured":"Ramharack R, Barkalow D, Spahr MA. Dominant negative effect of TGF-beta1 and TNF-alpha on basal and IL-6-induced lipoprotein(a) and apolipoprotein(a) mRNA expression in primary monkey hepatocyte cultures. Arterioscler Thromb Vasc Biol. 1998;18(6):984\u201390.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"3289_CR50","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/hep.30626","volume":"70","author":"A Lonardo","year":"2019","unstructured":"Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, Abdelmalek MF, Suzuki A. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology (Baltimore MD). 2019;70(4):1457\u201369.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"4","key":"3289_CR51","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11901-021-00568-8","volume":"20","author":"J Musto","year":"2021","unstructured":"Musto J, Spengler EK, German MN. Sexual dimorphisms in nonalcoholic fatty liver disease. Curr Hepatol Rep. 2021;20(4):97\u2013107.","journal-title":"Curr Hepatol Rep"},{"issue":"5","key":"3289_CR52","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4254\/wjh.v6.i5.274","volume":"6","author":"JJ Pan","year":"2014","unstructured":"Pan JJ, Fallon MB. Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol. 2014;6(5):274\u201383.","journal-title":"World J Hepatol"},{"issue":"2","key":"3289_CR53","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1001\/archinte.158.2.134","volume":"158","author":"B Gaster","year":"1998","unstructured":"Gaster B, Hirsch IB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med. 1998;158(2):134\u201340.","journal-title":"Arch Intern Med"},{"issue":"1","key":"3289_CR54","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12933-024-02389-7","volume":"23","author":"M Lejawa","year":"2024","unstructured":"Lejawa M, Go\u0142awski M, Fronczek M, Osadnik T, Paneni F, Ruscica M, Pawlas N, Lisik M, Banach M. Causal associations between insulin and Lp(a) levels in Caucasian population: a Mendelian randomization study. Cardiovasc Diabetol. 2024;23(1):316.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"3289_CR55","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244\u201355.","journal-title":"N Engl J Med"},{"issue":"17","key":"3289_CR56","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1056\/NEJMe2503824","volume":"392","author":"DJ Rader","year":"2025","unstructured":"Rader DJ. Targeting lipoprotein(a) - the next frontier in cardiovascular disease. N Engl J Med. 2025;392(17):1740\u20132.","journal-title":"N Engl J Med"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-026-03289-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03289-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03289-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:02:56Z","timestamp":1783951376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-026-03289-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,12]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3289"],"URL":"https:\/\/doi.org\/10.1186\/s12933-026-03289-8","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,12]]},"assertion":[{"value":"10 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R.D.S. has received honoraria for consulting, research, or speaking from Amgen, Ach\u00e9, Arrowhead, Biolab, Daiichi Sankyo, Esperion, Eli Lilly, Ionis, MSD, Novo Nordisk, Novartis, Torrent, Sanofi\/Regeneron, and Ultragenyx. E.S.T has received honoraria related to consulting, research and or speaker activities from Novartis, Amgen, Sanofi and Sobi.C.T. has received honoraria related to consulting, research, and or speaker activities from Medtronic, Microport, Philips, Biotronik, Innova and Shockwave.All other authors have no conflicts of interest to disclose related to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"In SHIP-START-0, the study was approved by the ethics committee of the Faculty of Medicine at the University of Greifswald (BB 39\/08). All participants provided written informed consent before enrolment in the study, which was conducted in accordance with the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All study participants gave written informed consent to participate in this study, and having their results published as part of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"203"}}